A Phase 3 interventional study of CYD Dengue Vaccine and CYD Dengue Vaccine in Dengue Fever, Dengue Hemorrhagic Fever and Human Papillomavirus Disease, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 1 site in Mexico. Open to female participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Severe Dengue by Sanofi — none open to participants now, none under way, none of them phase 3. Severe Dengue · Sanofi.
Among the 29 studies in Severe Dengue by Sanofi, this one is the 12th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2016, is one of 9 in phase 3, and was the 27th registered.
65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.
Browse Severe Dengue studies →None of the 29 studies in Severe Dengue by Sanofi is open now. The open studies under Severe Dengue, anywhere →
Of the 4 Severe Dengue studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 9 Years to 14 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 7 started in 2016.
This study's enrollment of 480 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.
Median enrollment 345 across the 26 interventional studies, 3,203 across the 3 observational. Of the 29 that completed or were terminated, 24 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Severe Dengue by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.
Primary objectives:
Secondary Objectives:
Participants received 3 doses of the CYD dengue vaccine and 2 doses of Cervarix administered either concomitantly or sequentially. Due to a protocol amendment, only previously dengue exposed participants (seropositive for dengue before vaccination) were eligible to complete the vaccination schedule and be assessed for CYD immunogenicity and human papilloma virus (HPV) immunogenicity. Dengue unexposed participants (seronegative for dengue before vaccination) did not receive the third CYD dengue vaccine injection, but were followed for safety up to 6 months after the last injection.
Safety assessments included solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period. All participants were included in the assessment of safety up to 6 months after the last injection.
65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.
This study's enrollment of 480 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.
Browse Severe Dengue studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
Biological: CYD Dengue Vaccine · Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
Biological: CYD Dengue Vaccine · Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
0.5 mL, SC at Day 0, Months 6 and 12
Also known as: Dengvaxia®
0.5 mL, SC at Months 1, 7, and 13
Also known as: Dengvaxia®
Drug page: Human papillomavirus vaccine, L1 type 16, 18Studies of Human papillomavirus vaccine, L1 type 16, 18Human papillomavirus vaccine, L1 type 16, 18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, IM at Day 0 and Month 6
Also known as: Cervarix®
Drug page: Human papillomavirus vaccine, L1 type 16, 18Studies of Human papillomavirus vaccine, L1 type 16, 18Human papillomavirus vaccine, L1 type 16, 18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, IM at Day 0 and Month 6
Also known as: Cervarix®
Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously Dengue Seropositive Participants
GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an enzyme-linked immunosorbent assay (ELISA) method. Dengue seropositive participants at baseline were defined as those participants with titers greater than or equal to (\>=) 10 (1/dilutions \[dil\]) for at least one serotype with the parental dengue virus strain.
Time frame: 28 days after the last Cervarix vaccination
GMTs Against Each Dengue Virus Serotype 28 Days After the Third CYD Dengue Vaccination in the Previously Dengue Seropositive Participants
The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
Time frame: 28 days after third CYD dengue vaccination
GMTs Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) at Day 0 and 28 Days After Each Cervarix Vaccination in the Previously Dengue Seropositive Participants
The GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
Time frame: Day 0 and 28 days after each Cervarix vaccination
Percentage of Participants With Seroconversion Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) 28 Days After Each Dose of Cervarix Vaccination in the Previously Dengue Seropositive Participants
Neutralizing antibodies against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Seroconversion was defined as changing serostatus from seronegative at baseline to seropositive (greater than \[\>\] lower limit of quantitation \[LLOQ\] of the assay) or \>=4-fold rise in antibody titer if seropositive at baseline (i.e., at least one antibody levels against Cervarix HPV antigens \> LLOQ at baseline). The LLOQ for HPV-16 and HPV-18 was less than (\<) 2.0 International Units per milliliter (IU/mL).
Time frame: 28 days after each Cervarix vaccination
GMTs Against Each Dengue Virus Serotype of CYD Dengue Vaccine at Day 0 and 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants
The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the PRNT50 assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
Time frame: Day 0 and 28 days after each CYD dengue vaccine vaccination
Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against Each of the 4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
Time frame: Day 0 and 28 days after each CYD dengue vaccine vaccination
Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against At Least 1,2,3,or4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in Previously Dengue Seropositive Participants
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
Time frame: Day 0 and 28 days after each CYD dengue vaccination
Percentage of Participants With Neutralizing Antibody Titers Above Pre-defined Thresholds Against Each Dengue Virus Serotypes of CYD at Baseline And 28 Days After Each Dose of CYD Dengue Vaccination in Dengue Seropositive Participants
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\<10, \>=10 and \>=100 \[1/dil\]) against each dengue virus serotypes of CYD were reported.
Time frame: Day 0 and 28 days after each CYD dengue vaccination
Number of Participants Reporting Immediate Adverse Events (AEs) Following Vaccination With Cervarix or CYD Dengue Vaccine
Any unsolicited systemic AE occurred during the first 30 minutes post-vaccination was recorded on the case report form (CRF) as immediate AE.
Time frame: Within 30 minutes after each and any vaccination
Number of Participants Reporting Solicited Injection Site Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine
Solicited injection site reactions included pain, erythema, and swelling.
Time frame: Up to 7 days after each and any vaccination
Number of Participants Reporting Solicited Systemic Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine
Solicited systemic reactions included Fever, Headache, Malaise, Myalgia, and Asthenia. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.
Time frame: Up to 14 days after any and each vaccination
Number of Participants Reporting Unsolicited AEs Following Vaccination With Cervarix or CYD Dengue Vaccine
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.
Time frame: Up to 28 days after any and each vaccination
Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Cervarix or CYD Dengue Vaccine
AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.
Time frame: Up to 7 days after any and each vaccination
Number of Participants Reporting Serious Adverse Events (SAEs) Including Serious AESIs Following Vaccination With Cervarix or CYD Dengue Vaccine
An SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. An AESIs were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.
Time frame: From Day 0 up to 6 months after the last CYD or Cervarix vaccination
Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine
Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.
Time frame: From Day 0 up to 6 months after the last CYD or Cervarix vaccination
Study participants were enrolled from 16 November 2016 to 13 March 2017 at 3 centers in Mexico.
| Milestone | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Started | 239 | 241 |
| Safety analysis set | 237 | 241 |
| Completed | 144 | 140 |
| Not completed | 95 | 101 |
| Withdrew: Non compliance with the protocol | 78 | 82 |
| Withdrew: Consent withdrawn by participant | 11 | 18 |
| Withdrew: Lost to follow-up | 6 | 1 |
GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an enzyme-linked immunosorbent assay (ELISA) method. Dengue seropositive participants at baseline were defined as those participants with titers greater than or equal to (\>=) 10 (1/dilutions \[dil\]) for at least one serotype with the parental dengue virus strain.
| Endotoxin Units per milliliter (EU/mL) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| HPV-16 | 2149 (1877 to 2460) | 2268 (1946 to 2644) |
| HPV-18 | 833 (727 to 954) | 845 (723 to 987) |
The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
| titer (1/dilution) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Serotype 1 | 384 (291 to 507) | 393 (292 to 528) |
| Serotype 2 | 670 (535 to 839) | 735 (575 to 940) |
| Serotype 3 | 357 (305 to 418) | 388 (325 to 463) |
| Serotype 4 | 247 (213 to 287) | 265 (220 to 320) |
The GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
| EU/mL | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| HPV-16: Day 0 | 1.61 (1.31 to 1.97) | 1.58 (1.29 to 1.93) |
| HPV-16: 28 days post vaccination 1 | 118 (98.7 to 142) | 140 (116 to 170) |
| HPV-16: 28 days post vaccination 2 | 2089 (1852 to 2356) | 2162 (1869 to 2501) |
| HPV-18: Day 0 | 1.34 (1.15 to 1.55) | 1.34 (1.16 to 1.54) |
| HPV-18: 28 days post vaccination 1 | 53.8 (44.1 to 65.7) | 68.6 (56.5 to 83.4) |
| HPV-18: 28 days post vaccination 2 | 846 (752 to 951) | 846 (728 to 984) |
Neutralizing antibodies against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Seroconversion was defined as changing serostatus from seronegative at baseline to seropositive (greater than \[\>\] lower limit of quantitation \[LLOQ\] of the assay) or \>=4-fold rise in antibody titer if seropositive at baseline (i.e., at least one antibody levels against Cervarix HPV antigens \> LLOQ at baseline). The LLOQ for HPV-16 and HPV-18 was less than (\<) 2.0 International Units per milliliter (IU/mL).
| percentage of participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| HPV-16: 28 days post-vaccination 1 | 98.0 (94.3 to 99.6) | 99.3 (96.4 to 100.0) |
| HPV-16: 28 days post-vaccination 2 | 98.7 (95.2 to 99.8) | 99.3 (96.3 to 100.0) |
| HPV-18: 28 days post-vaccination 1 | 100.0 (97.6 to 100.0) | 98.7 (95.3 to 99.8) |
| HPV-18: 28 days post-vaccination 2 | 99.3 (96.3 to 100.0) | 100.0 (97.5 to 100.0) |
The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the PRNT50 assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
| titer (1/dilution) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Serotype 1: Day 0 | 150 (99.7 to 225) | 108 (72.1 to 163) |
| Serotype 1: 28 days post-vaccination 1 | 711 (498 to 1016) | 586 (409 to 840) |
| Serotype 1: 28 days post-vaccination 2 | 460 (336 to 630) | 476 (337 to 674) |
| Serotype 1: 28 days post-vaccination 3 | 384 (291 to 507) | 393 (292 to 528) |
| Serotype 2: Day 0 | 193 (141 to 263) | 188 (135 to 262) |
| Serotype 2: 28 days post-vaccination 1 | 1168 (879 to 1552) | 1163 (847 to 1597) |
| Serotype 2: 28 days post-vaccination 2 | 618 (492 to 776) | 703 (541 to 913) |
| Serotype 2: 28 days post-vaccination 3 | 670 (535 to 839) | 735 (575 to 940) |
| Serotype 3: Day 0 | 98.5 (72.2 to 135) | 90.2 (67.2 to 121) |
| Serotype 3: 28 days post-vaccination 1 | 499 (386 to 644) | 503 (385 to 656) |
| Serotype 3: 28 days post-vaccination 2 | 299 (251 to 358) | 361 (294 to 445) |
| Serotype 3: 28 days post-vaccination 3 | 357 (305 to 418) | 388 (325 to 463) |
| Serotype 4: Day 0 | 47.1 (34.6 to 64.0) | 38.0 (28.4 to 50.9) |
| Serotype 4: 28 days post-vaccination 1 | 423 (336 to 532) | 449 (365 to 552) |
| Serotype 4: 28 days post-vaccination 2 | 267 (225 to 316) | 262 (219 to 314) |
| Serotype 4: 28 days post-vaccination 3 | 247 (213 to 287) | 265 (220 to 320) |
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
| percentage of participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Serotype 1: Day 0 | 74.0 (66.4 to 80.8) | 68.9 (60.8 to 76.2) |
| Serotype 1: 28 days post-vaccination 1 | 94.7 (89.8 to 97.7) | 95.3 (90.5 to 98.1) |
| Serotype 1: 28 days post-vaccination 2 | 97.3 (93.3 to 99.3) | 97.3 (93.1 to 99.2) |
| Serotype 1: 28 days post-vaccination 3 | 99.3 (96.2 to 100.0) | 97.9 (93.9 to 99.6) |
| Serotype 2: Day 0 | 92.9 (87.6 to 96.4) | 91.4 (85.7 to 95.3) |
| Serotype 2: 28 days post-vaccination 1 | 96.7 (92.4 to 98.9) | 93.9 (88.8 to 97.2) |
| Serotype 2: 28 days post-vaccination 2 | 100.0 (97.6 to 100.0) | 98.6 (95.1 to 99.8) |
| Serotype 2: 28 days post-vaccination 3 | 100.0 (97.5 to 100.0) | 100.0 (97.4 to 100.0) |
| Serotype 3: Day 0 | 82.5 (75.5 to 88.1) | 83.4 (76.5 to 89.0) |
| Serotype 3: 28 days post-vaccination 1 | 96.7 (92.4 to 98.9) | 96.6 (92.3 to 98.9) |
| Serotype 3: 28 days post-vaccination 2 | 99.3 (96.3 to 100.0) | 100.0 (97.5 to 100.0) |
| Serotype 3: 28 days post-vaccination 3 | 99.3 (96.2 to 100.0) | 100.0 (97.4 to 100.0) |
| Serotype 4: Day 0 | 68.8 (60.9 to 76.0) | 66.9 (58.8 to 74.3) |
| Serotype 4: 28 days post-vaccination 1 | 97.3 (93.3 to 99.3) | 98.6 (95.2 to 99.8) |
| Serotype 4: 28 days post-vaccination 2 | 100.0 (97.6 to 100.0) | 100.0 (97.5 to 100.0) |
| Serotype 4: 28 days post-vaccination 3 | 100.0 (97.5 to 100.0) | 98.6 (94.9 to 99.8) |
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.
| percentage of participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| At least 1 Serotype: Day 0 | 100.0 (97.6 to 100.0) | 100.0 (97.6 to 100.0) |
| At least 1 Serotype: 28 days post-vaccination 1 | 99.3 (96.3 to 100.0) | 99.3 (96.3 to 100.0) |
| At least 1 Serotype: 28 days post-vaccination 2 | 100.0 (97.6 to 100.0) | 100.0 (97.5 to 100.0) |
| At least 1 Serotype: 28 days post-vaccination 3 | 100.0 (97.5 to 100.0) | 100.0 (97.4 to 100.0) |
| At least 2 Serotype: Day 0 | 84.4 (77.7 to 89.8) | 82.8 (75.8 to 88.4) |
| At least 2 Serotype: 28 days post-vaccination 1 | 98.0 (94.3 to 99.6) | 98.0 (94.2 to 99.6) |
| At least 2 Serotype: 28 days post-vaccination 2 | 100.0 (97.6 to 100.0) | 100.0 (97.5 to 100.0) |
| At least 2 Serotype: 28 days post-vaccination 3 | 100.0 (97.5 to 100.0) | 100.0 (97.4 to 100.0) |
| At least 3 Serotype: Day 0 | 74.0 (66.4 to 80.8) | 72.8 (65.0 to 79.8) |
| At least 3 Serotype: 28 days post-vaccination 1 | 95.3 (90.6 to 98.1) | 94.6 (89.6 to 97.6) |
| At least 3 Serotype: 28 days post-vaccination 2 | 99.3 (96.3 to 100.0) | 98.6 (95.1 to 99.8) |
| At least 3 Serotype: 28 days post-vaccination 3 | 100.0 (97.5 to 100.0) | 98.6 (94.9 to 99.8) |
| All 4 Serotypes: Day 0 | 59.7 (51.5 to 67.6) | 55.0 (46.7 to 63.1) |
| All 4 Serotypes: 28 days post-vaccination 1 | 92.7 (87.3 to 96.3) | 92.6 (87.1 to 96.2) |
| All 4 Serotypes: 28 days post-vaccination 2 | 97.3 (93.3 to 99.3) | 97.3 (93.1 to 99.2) |
| All 4 Serotypes: 28 days post-vaccination 3 | 98.6 (95.0 to 99.8) | 97.9 (93.9 to 99.6) |
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\<10, \>=10 and \>=100 \[1/dil\]) against each dengue virus serotypes of CYD were reported.
| percentage of participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Serotype 1: Pre-vaccination 1 <10 (1/dil) | 26.0 (19.2 to 33.6) | 31.1 (23.8 to 39.2) |
| Serotype 1: Pre-vaccination 1 >=10 (1/dil) | 74.0 (66.4 to 80.8) | 68.9 (60.8 to 76.2) |
| Serotype 1: Pre-vaccination 1 >=100 (1/dil) | 61.0 (52.9 to 68.8) | 56.3 (48.0 to 64.3) |
| Serotype 1: Post-vaccination 1 <10 (1/dil) | 5.3 (2.3 to 10.2) | 4.7 (1.9 to 9.5) |
| Serotype 1: Post-vaccination 1 >=10 (1/dil) | 94.7 (89.8 to 97.7) | 95.3 (90.5 to 98.1) |
| Serotype 1: Post-vaccination 1 >=100 (1/dil) | 82.0 (74.9 to 87.8) | 78.4 (70.9 to 84.7) |
| Serotype 1: Post-vaccination 2 <10 (1/dil) | 2.7 (0.7 to 6.7) | 2.7 (0.8 to 6.9) |
| Serotype 1: Post-vaccination 2 >=10 (1/dil) | 97.3 (93.3 to 99.3) | 97.3 (93.1 to 99.2) |
| Serotype 1: Post-vaccination 2 >=100 (1/dil) | 77.2 (69.6 to 83.7) | 72.6 (64.6 to 79.7) |
| Serotype 1: Post-vaccination 3 <10 (1/dil) | 0.7 (0.0 to 3.8) | 2.1 (0.4 to 6.1) |
| Serotype 1: Post-vaccination 3 >=10 (1/dil) | 99.3 (96.2 to 100.0) | 97.9 (93.9 to 99.6) |
| Serotype 1: Post-vaccination 3 >=100 (1/dil) | 74.8 (66.9 to 81.7) | 76.4 (68.5 to 83.2) |
| Serotype 2: Pre-vaccination 1 <10 (1/dil) | 7.1 (3.6 to 12.4) | 8.6 (4.7 to 14.3) |
| Serotype 2: Pre-vaccination 1 >=10 (1/dil) | 92.9 (87.6 to 96.4) | 91.4 (85.7 to 95.3) |
| Serotype 2: Pre-vaccination 1 >=100 (1/dil) | 59.1 (50.9 to 66.9) | 61.6 (53.3 to 69.4) |
| Serotype 2: Post-vaccination 1 <10 (1/dil) | 3.3 (1.1 to 7.6) | 6.1 (2.8 to 11.2) |
| Serotype 2: Post-vaccination 1 >=10 (1/dil) | 96.7 (92.4 to 98.9) | 93.9 (88.8 to 97.2) |
| Serotype 2: Post-vaccination 1 >=100 (1/dil) | 91.3 (85.6 to 95.3) | 91.9 (86.3 to 95.7) |
| Serotype 2: Post-vaccination 2 <10 (1/dil) | 0.0 (0.0 to 2.4) | 1.4 (0.2 to 4.9) |
| Serotype 2: Post-vaccination 2 >=10 (1/dil) | 100.0 (97.6 to 100.0) | 98.6 (95.1 to 99.8) |
| Serotype 2: Post-vaccination 2 >=100 (1/dil) | 90.6 (84.7 to 94.8) | 90.4 (84.4 to 94.7) |
| Serotype 2: Post-vaccination 3 <10 (1/dil) | 0.0 (0.0 to 2.5) | 0.0 (0.0 to 2.6) |
| Serotype 2: Post-vaccination 3 >=10 (1/dil) | 100.0 (97.5 to 100.0) | 100.0 (97.4 to 100.0) |
| Serotype 2: Post-vaccination 3 >=100 (1/dil) | 95.1 (90.2 to 98.0) | 90.7 (84.6 to 95.0) |
| Serotype 3: Pre-vaccination 1 <10 (1/dil) | 17.5 (11.9 to 24.5) | 16.6 (11.0 to 23.5) |
| Serotype 3: Pre-vaccination 1 >=10 (1/dil) | 82.5 (75.5 to 88.1) | 83.4 (76.5 to 89.0) |
| Serotype 3: Pre-vaccination 1 >=100 (1/dil) | 51.3 (43.1 to 59.4) | 49.0 (40.8 to 57.3) |
| Serotype 3: Post-vaccination 1 <10 (1/dil) | 3.3 (1.1 to 7.6) | 3.4 (1.1 to 7.7) |
| Serotype 3: Post-vaccination 1 >=10 (1/dil) | 96.7 (92.4 to 98.9) | 96.6 (92.3 to 98.9) |
| Serotype 3: Post-vaccination 1 >=100 (1/dil) | 88.7 (82.5 to 93.3) | 87.8 (81.5 to 92.6) |
| Serotype 3: Post-vaccination 2 <10 (1/dil) | 0.7 (0.0 to 3.7) | 0.0 (0.0 to 2.5) |
| Serotype 3: Post-vaccination 2 >=10 (1/dil) | 99.3 (96.3 to 100.0) | 100.0 (97.5 to 100.0) |
| Serotype 3: Post-vaccination 2 >=100 (1/dil) | 87.2 (80.8 to 92.1) | 87.0 (80.4 to 92.0) |
| Serotype 3: Post-vaccination 3 <10 (1/dil) | 0.7 (0.0 to 3.8) | 0.0 (0.0 to 2.6) |
| Serotype 3: Post-vaccination 3 >=10 (1/dil) | 99.3 (96.2 to 100.0) | 100.0 (97.4 to 100.0) |
| Serotype 3: Post-vaccination 3 >=100 (1/dil) | 94.4 (89.3 to 97.6) | 90.7 (84.6 to 95.0) |
| Serotype 4: Pre-vaccination 1 <10 (1/dil) | 31.2 (24.0 to 39.1) | 33.1 (25.7 to 41.2) |
| Serotype 4: Pre-vaccination 1 >=10 (1/dil) | 68.8 (60.9 to 76.0) | 66.9 (58.8 to 74.3) |
| Serotype 4: Pre-vaccination 1 >=100 (1/dil) | 33.1 (25.8 to 41.1) | 29.8 (22.6 to 37.8) |
| Serotype 4: Post-vaccination 1 <10 (1/dil) | 2.7 (0.7 to 6.7) | 1.4 (0.2 to 4.8) |
| Serotype 4: Post-vaccination 1 >=10 (1/dil) | 97.3 (93.3 to 99.3) | 98.6 (95.2 to 99.8) |
| Serotype 4: Post-vaccination 1 >=100 (1/dil) | 87.3 (80.9 to 92.2) | 89.9 (83.8 to 94.2) |
| Serotype 4: Post-vaccination 2 <10 (1/dil) | 0.0 (0.0 to 2.4) | 0.0 (0.0 to 2.5) |
| Serotype 4: Post-vaccination 2 >=10 (1/dil) | 100.0 (97.6 to 100.0) | 100.0 (97.5 to 100.0) |
| Serotype 4: Post-vaccination 2 >=100 (1/dil) | 82.6 (75.5 to 88.3) | 80.1 (72.7 to 86.3) |
| Serotype 4: Post-vaccination 3 <10 (1/dil) | 0.0 (0.0 to 2.5) | 1.4 (0.2 to 5.1) |
| Serotype 4: Post-vaccination 3 >=10 (1/dil) | 100.0 (97.5 to 100.0) | 98.6 (94.9 to 99.8) |
| Serotype 4: Post-vaccination 3 >=100 (1/dil) | 83.2 (76.1 to 88.9) | 83.6 (76.4 to 89.3) |
Any unsolicited systemic AE occurred during the first 30 minutes post-vaccination was recorded on the case report form (CRF) as immediate AE.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| After any CYD/Cervarix vaccination | 0 | 0 |
| Post CYD/Cervarix vaccination 1 | 0 | 0 |
| Post CYD/Cervarix vaccination 2 | 0 | 0 |
| Post CYD vaccination 3 | 0 | 0 |
Solicited injection site reactions included pain, erythema, and swelling.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Pain: Post any CYD/Cervarix vaccine | 212 | 221 |
| Pain: Post CYD/Cervarix vaccination 1 | 202 | 206 |
| Pain: Post CYD/Cervarix vaccination 2 | 173 | 169 |
| Pain: Post CYD vaccination 3 | 65 | 59 |
| Erythema: Post any CYD/Cervarix vaccine | 64 | 61 |
| Erythema: Post CYD/Cervarix vaccination 1 | 49 | 43 |
| Erythema: Post CYD/Cervarix vaccination 2 | 41 | 34 |
| Erythema: Post CYD vaccination 3 | 6 | 11 |
| Swelling: Post any CYD/Cervarix vaccine | 73 | 60 |
| Swelling: Post CYD/Cervarix vaccination 1 | 55 | 44 |
| Swelling: Post CYD/Cervarix vaccination 2 | 48 | 35 |
| Swelling: Post CYD vaccination 3 | 8 | 10 |
Solicited systemic reactions included Fever, Headache, Malaise, Myalgia, and Asthenia. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Fever: Post any vaccination | 25 | 35 |
| Fever: Post vaccination 1 (Visit 1) | 14 | 8 |
| Fever: Post CYD vaccination 1 (Visit 2) | — | 14 |
| Fever: Post vaccination 2 (Visit 4) | 10 | 12 |
| Fever: Post CYD vaccination 2 (Visit 5) | — | 8 |
| Fever: Post CYD vaccination 3 (Visit 7) | 5 | 3 |
| Headache: Post any vaccination | 101 | 111 |
| Headache: Post vaccination 1 (Visit 1) | 83 | 69 |
| Headache: Post CYD vaccination 1 (Visit 2) | — | 54 |
| Headache: Post vaccination 2 (Visit 4) | 47 | 48 |
| Headache: Post CYD vaccination 2 (Visit 5) | — | 36 |
| Headache: Post CYD vaccination 3 (Visit 7) | 18 | 15 |
| Malaise: Post any vaccination | 113 | 133 |
| Malaise: Post vaccination 1 (Visit 1) | 84 | 84 |
| Malaise: Post CYD vaccination 1 (Visit 2) | — | 56 |
| Malaise: Post vaccination 2 (Visit 4) | 73 | 72 |
| Malaise: Post CYD vaccination 2 (Visit 5) | — | 47 |
| Malaise: Post CYD vaccination 3 (Visit 7) | 19 | 28 |
| Myalgia: Post any vaccination | 160 | 168 |
| Myalgia: Post vaccination 1 (Visit 1) | 129 | 124 |
| Myalgia: Post CYD vaccination 1 (Visit 2) | — | 76 |
| Myalgia: Post vaccination 2 (Visit 4) | 96 | 95 |
| Myalgia: Post CYD vaccination 2 (Visit 5) | — | 60 |
| Myalgia: Post CYD vaccination 3 (Visit 7) | 26 | 31 |
| Asthenia: Post any vaccination | 93 | 95 |
| Asthenia: Post vaccination 1 (Visit 1) | 72 | 53 |
| Asthenia: Post CYD vaccination 1 (Visit 2) | — | 47 |
| Asthenia: Post vaccination 2 (Visit 4) | 51 | 35 |
| Asthenia: Post CYD vaccination 2 (Visit 5) | — | 30 |
| Asthenia: Post CYD vaccination 3 (Visit 7) | 16 | 13 |
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Post any vaccination | 50 | 76 |
| Post vaccination 1 (Visit 1) | 33 | 37 |
| Post CYD vaccination 1 (Visit 2) | — | 25 |
| Post vaccination 2 (Visit 4) | 26 | 23 |
| Post CYD vaccination 2 (Visit 5) | — | 15 |
| Post CYD vaccination 3 (Visit 7) | 5 | 5 |
AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Post any CYD/Cervarix vaccination | 0 | 0 |
| Post CYD/Cervarix vaccination 1 | 0 | 0 |
| Post CYD/Cervarix vaccination 2 | 0 | 0 |
| Post CYD/Cervarix vaccination 3 | 0 | 0 |
An SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. An AESIs were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| SAE | 6 | 0 |
| Serious AESI | 0 | 0 |
Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.
| Participants | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) |
|---|---|---|
| Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine | 0 | 0 |
Collected over AE data were collected from Day 0 up to Day 28 post any vaccination. Solicited Reaction (SR) were collected from Day 0 up to Day 14 post vaccination. The SAEs were collected throughout the trial (up to Month 14), i.e,. 6 months after last CYD vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CYD Dengue Vaccine + Cervarix (Sequential Administration) | 0/237 (0%) | 6/237 (2.5%) | 222/237 (93.7%) |
| CYD Dengue Vaccine + Cervarix (Concomitant Administration) | 0/241 (0%) | 0/241 (0%) | 228/241 (94.6%) |
| Event | CYD Dengue Vaccine + Cervarix (Sequential Administration) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) |
|---|---|---|
| AppendicitisInfections and infestations | 1/237 | 0/241 |
| Forearm FractureInjury, poisoning and procedural complications | 1/237 | 0/241 |
| Gun Shot WoundInjury, poisoning and procedural complications | 1/237 | 0/241 |
| Radius FractureInjury, poisoning and procedural complications | 1/237 | 0/241 |
| Pre-EclampsiaPregnancy, puerperium and perinatal conditions | 1/237 | 0/241 |
| NephrolithiasisRenal and urinary disorders | 1/237 | 0/241 |
| Event | CYD Dengue Vaccine + Cervarix (Sequential Administration) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) |
|---|---|---|
| Injection Site PainGeneral disorders | 212/237 | 221/241 |
| MyalgiaMusculoskeletal and connective tissue disorders | 160/237 | 168/241 |
| MalaiseGeneral disorders | 113/237 | 133/241 |
| HeadacheNervous system disorders | 102/237 | 113/241 |
| AstheniaGeneral disorders | 93/237 | 95/241 |
| Injection Site SwellingGeneral disorders | 73/237 | 60/241 |
| Injection Site ErythemaGeneral disorders | 64/237 | 61/241 |
| PyrexiaGeneral disorders | 25/237 | 37/241 |
| NasopharyngitisInfections and infestations | 8/237 | 22/241 |
| PharyngitisInfections and infestations | 13/237 | 20/241 |
Baseline characteristics were analyzed on all randomized population which included participants for whom an injection group were allocated.
| Age, Continuous(years) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) | Total |
|---|---|---|---|
| Mean | 9.50 ± 1.00 | 9.56 ± 1.05 | 9.53 ± 1.03 |
| Sex: Female, Male(Participants) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) | Total |
|---|---|---|---|
| Female | 239 | 241 | 480 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | CYD Dengue Vaccine + Cervarix (Concomitant Administration) | CYD Dengue Vaccine + Cervarix (Sequential Administration) | Total |
|---|---|---|---|
| Race: Not reported | 239 | 241 | 480 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2016 to primary completion in Mar 2019, 28 months.
Results were first posted in Mar 2020, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human papillomavirus vaccine, L1 type 16, 18
Sanofi Pasteur, a Sanofi Company →